Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients.
R. Scherber, Ruben A. Mesa(Atrium Health Wake Forest Baptist), Pablo Muxí(Hospital Británico), Gunnar Birgegård(Uppsala University Hospital), Ayalew Tefferi(Mayo Clinic), Dolores Hernández‐Maraver(Centre Hospitalier Universitaire de Grenoble), Norman Maldonado(University of Puerto Rico System), A. C. Dueck, Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Federico Sackmann(Centre Hospitalier Universitaire de Grenoble), Jessica Samuelsson(Karolinska Institutet), Tiziano Barbui(University of Bergamo), Maria L Ferarri(Centre Hospitalier Universitaire de Grenoble), Petter Johansson, Giovanni Barosi(Policlinico San Matteo Fondazione), Jean‐Jacques Kiladjian(Délégation Paris 5), A. M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Francesco Passamonti(University of Milan)
Cited by 4
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k